Aprepitant and fosaprepitant drug interactions: a systematic review.

ABSTRACT:

Aims

Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity. This systematic review evaluates clinically significant pharmacokinetic drug interactions with aprepitant and fosaprepitant and describes adverse events ascribed to drug interactions with aprepitant or fosaprepitant.

Methods

We systematically reviewed the literature to September 11, 2016, to identify articles evaluating drug interactions involving aprepitant/fosaprepitant. The clinical significance of each reported pharmacokinetic drug interaction was evaluated based on the United States Food and Drug Administration guidance document on conducting drug interaction studies. The probability of an adverse event reported in case reports

SUBMITTER: Patel P 

PROVIDER: S-EPMC5595939 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature